RE104 safety and efficacy for postpartum depression
About this title
Read the official source — NCT06342310This study evaluated the safety and effectiveness of RE104 for Injection for people with depression.
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of RE104 for Injection for people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 37 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 84
- Sponsor
- Reunion Neuroscience Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT06342310
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Parallel-Group Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Patients With Postpartum Depression (PPD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Birmingham · Tucson · Santa Monica
31 more locations
- Boulder
- Denver
- Lauderhill
- Tampa
- Atlanta
- Decatur
- Marietta
- Savannah
- Honolulu
- Kansas City
- Shreveport
- Baltimore
- Rockville
- Springfield
- Novi
- Albuquerque
- Buffalo
- New York
- Chapel Hill
- Monroe
- Cleveland
- Columbus
- West Chester
- Austin
- Plano
- San Antonio
- Draper
- Salt Lake City
- Charlottesville
- Seattle
- Madison
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of RE104 for Injection for people with depression.
Who is behind this study?
The study sponsor is Reunion Neuroscience Inc.
Did this study involve medication?
Yes. The study involved medication, including RE104 for Injection.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
